4月13日，IDEAYA Biosciences（IDYA）今日盘前股价一度飙涨逾40%，引起了市场的广泛关注。
消息面上，该公司宣布其与施维雅（Servier）合作开发的Darovasertib与克唑替尼（Xalkori）组合疗法，在一线治疗HLA-A*02:01阴性转移性葡萄膜黑色素瘤的2/3期注册临床试验（OPTIMUM-02）中取得了积极的顶线结果，成功达到了主要研究终点。
独立中心影像评估确认，该组合疗法在主要疗效指标——中位无进展生存期方面展现出具有统计学意义的显著改善。具体数据显示，联合治疗组的中位生存期提高了6.9个月，而对照组仅为3.1个月，并且观察到了完全缓解病例。基于这些积极数据，公司计划在2026年下半年向美国食品药品监督管理局（FDA）提交新药申请，寻求加速批准路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
